Sudden cardiac death in athletes, although relatively uncommon, is a well-recognized condition generally associated with some congenital abnormalities. It, however, continues to be of vast interest to the public as athletes are seen as a distinct group of individuals who are especially able to tolerate more intense physical activities than the general population. Obviously, intense activities predispose susceptible athletes to sudden cardiac death, hence the importance of pre-participation screening tests. As the cost of healthcare continues to be on the rise, there will be increasing difficulty justifying a nation-wide method of screening cost-effectively. This article is intended to describe the possible underlying causes of sudden cardiac death discovered thus far, as well as methods for detection, pre-participation guidelines, and emerging therapy.

Keywords:
Athletes, Athlete’s heart, Sudden cardiac death, Syncope, Ventricular tachyarrhythmia
1.
Rich BS: Sudden death screening. Med Clin North Am 1994;78:267–288.
2.
Plymire DC: Running, heart disease, and the ironic death of Jim Fixx. Res Q Exerc Sport 2002;73:38–46.
3.
Maron BJ: Sudden death in young athletes. Lessons from the Hank Gathers affair (comment). N Engl J Med 1993;329:55–57.
4.
Van Camp SP: What can we learn from Reggie Lewis’s death. Phys Sportsmed 1993;21:73–87.
5.
Maron BJ, Epstein SE, Roberts WC: Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986;7:204–214.
6.
Van Camp SP, et al: Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc 1995;27:641–647.
7.
Maron BJ, et al: Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles (comment). JAMA 1996;276:199–204.
8.
Thompson PD, et al: Incidence of death during jogging in Rhode Island from 1975 through 1980. JAMA 1982;247:2535–2538.
9.
Maron BJ: Heart disease and other causes of sudden death in young athletes. Curr Probl Cardiol 1998;23:477–529.
10.
Maron BJ, Poliac LC, Roberts WO: Risk for sudden cardiac death associated with marathon running (comment). J Am Coll Cardiol 1996;28:428–431.
11.
Ades PA: Preventing sudden death: Cardiovascular screening of young athletes. Phys Sportsmed 1992;20:75–89.
12.
Ragosta M, et al: Death during recreational exercise in the State of Rhode Island. Med Sci Sports Exerc 1984;16:339–342.
13.
Siscovick DS, et al: The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med 1984;311:874–877.
14.
Burke AP, et al: Sports-related and non-sports-related sudden cardiac death in young adults. Am Heart J 1991;121:568–575.
15.
Corrado D, et al: Sudden death in young competitive athletes: Clinicopathologic correlations in 22 cases (comment). Am J Med 1990;89:588–596.
16.
Thiene G, et al: Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988;318:129–133.
17.
Suarez-Mier MP, Aguilera B: Causas de muerte subita asociada al deporte en Espana. Rev Esp Cardiol 2002;55:347–358.
18.
Bauce B, et al: Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42–43 (comment). Am J Cardiol 2000;85:573–579.
19.
Nava A, et al: Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000;36:2226–2233.
20.
Rampazzo A, et al; The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23–q24. Hum Mol Genet 1994;3:959–962.
21.
Rampazzo A, et al: A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42–q43. Hum Mol Genet 1995;4:2151–2154.
22.
Rampazzo A, et al: Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002;71:1200–1206.
23.
Rampazzo A, et al: ARVD4, a new locus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm. Genomics 1997;45:259–263.
24.
Tiso N, et al: Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001;10:189–194.
25.
Severini GM, et al: A new locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14. Genomics 1996;31:193–200.
26.
Li D, et al: The locus of a novel gene responsible for arrhythmogenic right-ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10p12–p14. Am J Hum Genet 2000;66:148–156.
27.
Li D, et al: Human protein tyrosine phosphatase-like gene: Expression profile, genomic structure, and mutation analysis in families with ARVD. Gene 2000;256:237–243.
28.
Ahmad F, et al: Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. Circulation 1998;98:2791–2795.
29.
Opie LH: Sudden death and sport. Lancet 1975;i:263–266.
30.
Northcote RJ, Ballantyne D: Sudden cardiac death in sport. Br Med J 1983;287:1357–1359.
31.
Virmani R, Robinowitz M: Cardiac pathology and sports medicine. Hum Pathol 1987;18:493–501.
32.
Maron BJ, et al: Sudden death in young athletes. Circulation 1980;62:218–229.
33.
Tsung SH, Huang TY, Chang HH: Sudden death in young athletes. Arch Pathol Lab Med 1982;106:168–170.
34.
Noakes TD, et al: Autopsy-proved coronary atherosclerosis in marathon runners. N Engl J Med 1979;301:86–89.
35.
Waller BF, Roberts WC: Sudden death while running in conditioned runners aged 40 years or over. Am J Cardiol 1980;45:1292–1300.
36.
Jackson RT, Beaglehole R, Sharpe N: Sudden death in runners. NZ Med J 1983;96:289–292.
37.
Thompson PD, et al: Death during jogging or running. A study of 18 cases. JAMA 1979;242:1265–1267.
38.
Maron BJ, Roberts WC, Epstein SE: Sudden death in hypertrophic cardiomyopathy: A profile of 78 patients. Circulation 1982;65:1388–1394.
39.
McKenna W, et al: Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532–538.
40.
Lambert EC, et al: Sudden unexpected death from cardiovascular disease in children. A cooperative international study. Am J Cardiol 1974;34:89–96.
41.
Maron BJ: Hypertrophic cardiomyopathy: A systematic review. JAMA 2002;287:1308–1320.
42.
Wigle ED, et al: Hypertrophic cardiomyopathy. Clinical spectrum and treatment (comment). Circulation 1995;92:1680–1692.
43.
Maron BJ, et al: Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 2000;102:858–864.
44.
Elliott PM, et al: Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol 2000;36:2212–2218.
45.
Braunwald E, Seidman CE, Sigwart U: Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation 2002;106:1312–1316.
46.
Maron BJ, et al: Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults (comment). Circulation 1995;92:785–789.
47.
Maron BJ, et al: Patterns of inheritance in hypertrophic cardiomyopathy: Assessment by M-mode and two-dimensional echocardiography. Am J Cardiol 1984;53:1087–1094.
48.
Schwartz K, et al: Molecular basis of familial cardiomyopathies. Circulation 1995;91:532–540.
49.
Marian AJ, Roberts R: Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995;92:1336–1347.
50.
Niimura H, et al: Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy (comment). N Engl J Med 1998;338:1248–1257.
51.
Watkins H, et al: Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058–1064.
52.
Watkins H, et al: Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy (comment). N Engl J Med 1992;326:1108–1114.
53.
Rosenzweig A, et al: Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes (comment). N Engl J Med 1991;325:1753–1760.
54.
Klues HG, Schiffers A, Maron BJ: Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699–1708.
55.
Maron BJ: Hypertrophic cardiomyopathy. Lancet 1997;350:127–133.
56.
Wigle ED, et al: Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985;28:1–83.
57.
Maron BJ, Pelliccia A, Spirito P: Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete’s heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995;91:1596–1601.
58.
Maron BJ, Klues HG: Surviving competitive athletics with hypertrophic cardiomyopathy. Am J Cardiol 1994;73:1098–1104.
59.
Maron BJ, et al: Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987;10:733–742.
60.
Nihoyannopoulos P, et al: Diastolic function in hypertrophic cardiomyopathy: Relation to exercise capacity (comment). J Am Coll Cardiol 1992;19:536–540.
61.
Ho CY, et al: Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy (comment). Circulation 2002;105:2992–2997.
62.
Sanderson JE, et al: Left ventricular filling in hypertrophic cardiomyopathy. An angiographic study. Br Heart J 1977;39:661–670.
63.
Sutton MG, et al: Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis. Circulation 1978;57:512–520.
64.
Hanrath P, et al: Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: An echocardiographic study. Am J Cardiol 1980;45:15–23.
65.
Bonow RO, et al: Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 1981;64:787–796.
66.
Maron BJ, et al: Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. Part 2. N Engl J Med 1987;316:844–852.
67.
Maron BJ, et al: Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. Part 1. N Engl J Med 1987;316:780–789.
68.
Maron BJ, et al: Intramural (‘small vessel’) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545–557.
69.
Tanaka M, et al: Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986;55:575–581.
70.
Tanaka M, et al: Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987;75:1130–1139.
71.
Cecchi F, et al: Hypertrophic cardiomyopathy in Tuscany: Clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529–1536.
72.
Robinson K, et al: Atrial fibrillation in hypertrophic cardiomyopathy: A longitudinal study (comment). J Am Coll Cardiol 1990;15:1279–1285.
73.
Basilico FC: Cardiovascular disease in athletes. Am J Sports Med 1999;27:108–121.
74.
Morganroth J, et al: Comparative left ventricular dimensions in trained athletes. Ann Intern Med 1975;82:521–524.
75.
Roeske WR, et al: Noninvasive evaluation of ventricular hypertrophy in professional athletes. Circulation 1976;53:286–291.
76.
Gilbert CA, et al: Echocardiographic study of cardiac dimensions and function in the endurance-trained athlete. Am J Cardiol 1977;40:528–533.
77.
Longhurst JC, et al: Echocardiographic left ventricular masses in distance runners and weight lifters. J Appl Physiol 1980;48:154–162.
78.
Nishimura T, Yamada Y, Kawai C: Echocardiographic evaluation of long-term effects of exercise on left ventricular hypertrophy and function in professional bicyclists. Circulation 1980;61:832–840.
79.
Fagard R, et al: Noninvasive assessment of seasonal variations in cardiac structure and function in cyclists. Circulation 1983;67:896–901.
80.
Fontaine G, et al: Arrhythmogenic right ventricular dysplasia. Annu Rev Med 1999;50:17–35.
81.
Lobo FV, et al: Right ventricular dysplasia: Morphological findings in 13 cases. Can J Cardiol 1992;8:261–268.
82.
Virmani R, et al: Sudden death and partial absence of the right ventricular myocardium: A report of three cases and a review of the literature. Arch Pathol Lab Med 1982;106:163–167.
83.
Metzger JT, et al: Value of the 12-lead electrocardiogram in arrhythmogenic right ventricular dysplasia, and absence of correlation with echocardiographic findings. Am J Cardiol 1993;72:964–967.
84.
Ricci C, et al: Magnetic resonance imaging in right ventricular dysplasia. Am J Cardiol 1992;70:1589–1595.
85.
Chu E, Cheitlin MD: Diagnostic considerations in patients with suspected coronary artery anomalies. Am Heart J 1993;126:1427–1438.
86.
Frescura C, et al: Anomalous origin of coronary arteries and risk of sudden death: A study based on an autopsy population of congenital heart disease (comment). Hum Pathol 1998;29:689–695.
87.
Basso C, et al: Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes (comment). J Am Coll Cardiol 2000;35:1493–1501.
88.
Virmani R, et al: Causes of sudden death in young and middle-aged competitive athletes. Cardiol Clin 1997;15:439–466.
89.
Yoshida K, Ogura Y, Wakasugi C: Sudden death case of single coronary artery with special reference to the effect of ischemia on actomyosin. Nippon Hoigaku Zasshi 1990;44:481–488.
90.
McClellan JT, Jokl E: Congenital anomalies of coronary arteries as cause of sudden death associated with physical exertion. Am J Clin Pathol 1968;50:229–233.
91.
Morales AR, Romanelli R, Boucek RJ: The mural left anterior descending coronary artery, strenuous exercise and sudden death. Circulation 1980;62:230–237.
92.
Bourassa MG, et al: Symptomatic myocardial bridges: Overview of ischemic mechanisms and current diagnostic and treatment strategies. J Am Coll Cardiol 2003;41:351–359.
93.
Winget JF, Capeless MA, Ades PA: Sudden death in athletes. Sports Med 1994;18:375–383.
94.
Emanuel R, et al: Formes frustes of Marfan’s syndrome presenting with severe aortic regurgitation. Clinicogenetic study of 18 families. Br Heart J 1977;39:190–197.
95.
Maron BJ, Garson A: Arrhythmias and sudden cardiac death in elite athletes. Cardiol Rev 1994;2:26–32.
96.
Maron BJ, Isner JM, McKenna WJ: 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24:880–885.
97.
Taliercio CP, et al: Idiopathic dilated cardiomyopathy in the young: Clinical profile and natural history. J Am Coll Cardiol 1985;6:1126–1131.
98.
Armstrong WF, McHenry PL: Ambulatory electrocardiographic monitoring: Can we predict sudden death? J Am Coll Cardiol 1985;5(6 suppl):13B–16B.
99.
von Olshausen K, et al: Ventricular arrhythmias in idiopathic dilated cardiomyopathy. Br Heart J1984;51:195–201.
100.
Hofmann T, et al: Mode of death in idiopathic dilated cardiomyopathy: A multivariate analysis of prognostic determinants. Am Heart J 1988;116:1455–1463.
101.
Huang J, et al: Prevalence of arrhythmias in patients with idiopathic dilated cardiomyopathy. Chin Med J 1994;107:176–180.
102.
Graham TP Jr, et al: 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 1: Congenital heart disease. J Am Coll Cardiol 1994;24:867–873.
103.
Cheitlin MD, Douglas PS, Parmley WW: 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 2: Acquired valvular heart disease. J Am Coll Cardiol 1994;24:874–880.
104.
Virmani R, Robinowitz M, McAllister HA Jr: Nontraumatic death in joggers. A series of 30 patients at autopsy. Am J Med 1982;72:874–882.
105.
Northcote RJ, Evans AD, Ballantyne D: Sudden death in squash players. Lancet 1984;i:148–150.
106.
Virmani R, Robinowitz M, McAllister HA Jr: Exercise and the heart. A review of cardiac pathology associated with physical activity. Pathol Annu 1985;20:431–462.
107.
Ludmerer KM, Kissane JM: Clinicopathologic conference: Sudden death in 47-year-old marathon runner. Am J Med 1984;76:517–526.
108.
Zipes DP, Garson A Jr: 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 6: Arrhythmias. J Am Coll Cardiol 1994;24:892–829.
109.
Gallagher JJ, et al: Wolff-Parkinson-White syndrome. The problem, evaluation, and surgical correction. Circulation 1975;51:767–785.
110.
Klein GJ, et al: Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979;301:1080–1085.
111.
Jervell FLN: Congenital deaf-mutism, functional heart disease with prolongation of the Q-Y interval and sudden death. Am Heart J 1957;54:59–68.
112.
Splawski I, et al: Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178–1185.
113.
Ackerman MJ: The long QT syndrome: Ion channel diseases of the heart. Mayo Clin Proc 1998;73:250–269.
114.
Jeresaty RM: Sudden death in the mitral valve prolapse-click syndrome. Am J Cardiol 1976;37:317–319.
115.
Chesler E, King RA, Edwards JE: The myxomatous mitral valve and sudden death. Circulation 1983;67:632–639.
116.
Pocock WA, et al: Sudden death in primary mitral valve prolapse. Am Heart J 1984;107:378–382.
117.
Maron BJ, et al: Clinical profile and spectrum of commotio cordis. JAMA 2002;287:1142–1146.
118.
Maron BJ, et al: Blunt impact to the chest leading to sudden death from cardiac arrest during sports activities (comment). N Engl J Med 1995;333:337–342.
119.
Luke JL, et al: Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: Pathological and toxicological findings. J Forensic Sci 1990;35:1441–1447.
120.
Lyngberg K: Myocardial infarction and death of a body builder after using anabolic steroids. Ugeskr Laeger 1991;153:587.
121.
Huston TP, Puffer JC, Rodney WM: The athletic heart syndrome. N Engl J Med 1985;313:24–32.
122.
Ehsani AA, Hagberg JM, Hickson RC: Rapid changes in left ventricular dimensions and mass in response to physical conditioning and deconditioning. Am J Cardiol 1978;42:52–56.
123.
Chapman JH: Profound sinus bradycardia in the athletic heart syndrome. J Sports Med Phys Fitness 1982;22:45–48.
124.
Wight JN Jr, Salem D: Sudden cardiac death and the ‘athlete’s heart’. Arch Intern Med 1995;155:1473–1480.
125.
Hanne-Paparo N, Kellermann JJ: Long-term Holter ECG monitoring of athletes. Med Sci Sports Exerc 1981;13:294–298.
126.
Zehender M, et al: ECG variants and cardiac arrhythmias in athletes: Clinical relevance and prognostic importance. Am Heart J 1990;119:1378–1391.
127.
Bjornstad H, et al: Electrocardiographic and echocardiographic findings in top athletes, athletic students and sedentary controls. Cardiology 1993;82:66–74.
128.
Bjornstad H, Storstein L, Meen HD: Electrocardiographic findings of left, right and septal hypertrophy in athletic students and sedentary controls. Cardiology 1993;82:56–65.
129.
Maron BJ: Structural features of the athlete heart as defined by echocardiography. J Am Coll Cardiol 1986;7:190–203.
130.
Ikaheimo MJ, Palatsi IJ, Takkunen JT: Noninvasive evaluation of the athletic heart: Sprinters versus endurance runners. Am J Cardiol 1979;44:24–30.
131.
Parker BM, et al: The noninvasive cardiac evaluation of long-distance runners. Chest 1978;73:376–381.
132.
Cohen JL, et al: The heart of a dancer: Noninvasive cardiac evaluation of professional ballet dancers. Am J Cardiol 1980;45:959–965.
133.
Bekaert I, et al: Non-invasive evaluation of cardiac function in professional cyclists. Br Heart J 1981;45:213–218.
134.
Lengyel M, Gyarfas I: The importance of echocardiography in the assessment of left ventricular hypertrophy in trained and untrained schoolchildren. Acta Cardiol 1979;34:63–69.
135.
Paulsen W, et al: Left ventricular function in marathon runners: Echocardiographic assessment. J Appl Physiol 1981;51:881–886.
136.
Zoneraich S, et al: Evaluating the endurance athlete’s heart: A non-invasive graphic study. Angiology 1979;30:223–239.
137.
Oakley DG, Oakley CM: Significance of abnormal electrocardiograms in highly trained athletes. Am J Cardiol 1982;50:985–989.
138.
Shapiro LM: Physiological left ventricular hypertrophy. Br Heart J 1984;52:130–135.
139.
Menapace FJ, et al: Left ventricular size in competitive weight lifters: An echocardiographic study. Med Sci Sports Exerc 1982;14:72–75.
140.
Muntz KH, Gonyea WJ, Mitchell JH: Cardiac hypertrophy in response to an isometric training program in the cat. Circ Res 1981;49:1092–1101.
141.
Mangrum JM, DiMarco JP: The evaluation and management of bradycardia. N Engl J Med 2000;342:703–709.
142.
Claessens P, et al: Physiological or pseudophysiological ECG changes in endurance-trained athletes. Heart Vessels 2000;15:181–190.
143.
James TN, Riddick L, Massing GK: Sickle cells and sudden death: Morphologic abnormalities of the cardiac conduction system (comment). J Lab Clin Med 1994;124:507–520.
144.
Kark JA, Ward FT: Exercise and hemoglobin S. Semin Hematol 1994;31:181–225.
145.
Brignole M, et al: Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001;22:1256–1306.
146.
Ammirati F, Colivicchi F, Santini M: Diagnosing syncope in clinical practice. Implementation of a simplified diagnostic algorithm in a multicentre prospective trial – the OESIL 2 study (Osservatorio Epidemiologico della Sincope nel Lazio) (comment). Eur Heart J 2000;21:935–940.
147.
Sarasin FP, et al: Prospective evaluation of patients with syncope: A population-based study (comment). Am J Med 2001;111:177–184.
148.
Maron BJ, et al: Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young). American Heart Association. Circulation 1996;94:850–856.
149.
Maron BJ, et al: Cardiovascular preparticipation screening of competitive athletes: Addendum: An addendum to a statement for health professionals from the Sudden Death Committee (Council on Clinical Cardiology) and the Congenital Cardiac Defects Committee (Council on Cardiovascular Disease in the Young). American Heart Association. Circulation 1998;97:2294.
150.
Maron BJ, et al: Results of screening a large group of intercollegiate competitive athletes for cardiovascular disease. J Am Coll Cardiol 1987;10:1214–1221.
151.
LaCorte MA, et al: EKG screening program for school athletes. Clin Cardiol 1989;12:42–44.
152.
Fuller CM: Cost effectiveness analysis of screening of high school athletes for risk of sudden cardiac death (comment). Med Sci Sports Exerc 2000;32:887–890.
153.
Fuller CM, et al: Prospective screening of 5,615 high school athletes for risk of sudden cardiac death (comment). Med Sci Sports & Exerc 1997;29:1131–1138.
154.
Ryan MP, et al: The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. Am J Cardiol 1995;76:689–694.
155.
Maron BJ, et al: Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 1983;51:189–194.
156.
Moss AJ, et al: The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84:1136–1144.
157.
Vincent GM, et al: The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome (comment). N Engl J Med 1992;327:846–852.
158.
Pelliccia A, et al: Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000;102:278–284.
159.
Biffi A, et al: Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes (comment). J Am Coll Cardiol 2002;40:446–452.
160.
Murry PM, et al: The role of limited echocardiography in screening athletes. Am J Cardiol 1995;76:849–850.
161.
McKenna WJ, et al: Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994;71:215–218.
162.
Maron BJ, et al: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy (comment). N Engl J Med 2000;342:365–373.
163.
Maron BJ, et al: Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003;107:2872–2875.
164.
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (comment). N Engl J Med 1997;337:1576–1583.
165.
Moss AJ, et al: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction (comment). N Engl J Med 2002;346:877–883.
166.
Gregoratos G, et al: ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002;106:2145–2161.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.